Evolent (EVH) Q4 2025 earnings review
Top-Line Boom Masks a Profitability Crater
Evolent is entering 2026 with a classic 'profitless prosperity' problem. While management is touting a massive ~33% revenue surge to ~$2.5B (driven by $900M in new Performance Suite launches), the bottom line is reversing. FY26 Adjusted EBITDA guidance of $110M-$140M implies a 17% YoY drop, compressing margins to roughly 5.0% from 8.1%. Add in a shocking $398M Q4 goodwill impairment, and the narrative of a disciplined, de-risked model is severely strained. Investors are being asked to absorb ACA Exchange membership headwinds and upfront contract reserving costs immediately, in exchange for a margin step-up that management promises won't arrive until late 2026.
🐂 Bull Case
The company successfully secured $900 million in new Performance Suite revenue for 2026. This proves their specialty cost management model remains highly demanded by health plans struggling with elevated medical trends.
Management expects operating cost reduction plans and the easing of new contract reserving effects to drive a rapid margin step-up by year-end 2026, positioning 2027 for a massive profitability tailwind.
🐻 Bear Case
A staggering $398 million Q4 goodwill impairment charge destroyed shareholder equity, signaling that historical acquisitions severely underperformed their carrying value.
Despite 33% top-line growth, FY26 Adjusted EBITDA is expected to decline by roughly 17%. The cost of launching new contracts and lost Exchange members are severely compressing near-term margins.
⚖️ Verdict: 🔴
Bearish. Management is hiding a margin collapse behind top-line growth. The $398M goodwill impairment is a massive red flag, and the guidance admits that the highly touted $900M in new contracts will actually drag down profitability throughout the first half of 2026.
Key Themes
EBITDA Growth is Reversing Despite Revenue Surge
Evolent's core narrative has been sustainable 20% EBITDA growth, but FY26 guidance officially breaks that trend. Despite booking $900M in new Performance Suite contracts, Adjusted EBITDA is reversing, dropping from $151.2M in FY25 to a midpoint of $125M in FY26. Management blames the 'reserving effects' of new contracts and a steep drop in ACA Exchange membership. This reveals the structural cash drag required to onboard new at-risk lives.
$398 Million Goodwill Impairment
A major red flag emerged in Q4: Evolent took a $398 million goodwill impairment charge. While management completely ignored this in their prepared quotes, a write-down of this magnitude explicitly contradicts their positive operational narrative. It indicates that previous M&A premiums (potentially tied to Machinify, OCP, or NIA) are now deemed unrecoverable, destroying past capital allocation value.
Performance Suite Bookings Accelerating
The top-line growth story is fully intact. Evolent is adding $900 million in new Performance Suite revenue in 2026. Health plans, battered by rising specialty care costs (especially in oncology and cardiology), are increasingly offloading risk to Evolent. This provides tremendous scale, assuming Evolent can successfully mature the margins on these new cohorts.
Medical Expense Ratio Remains Dangerously High
The cost to deliver care is eating up nearly all Performance Suite revenue. Evolent's Medical Expense Ratio (MER) excluding Evolent Care Partners was a staggering 94.8% in Q4 (and 89.0% for the full year). This leaves very little room for operating expenses and explains the fundamental pressure on the bottom line. Potential explanation: persistently elevated utilization in cardiology and the ACA Exchange 'benefit rush' seen late in the year.
AuthIntel and AI Automation Ramp-Up
To offset margin compression, management is heavily relying on their AI-first initiative, 'AuthIntel' (built on acquired Machinify assets). Evolent targets auto-approving over 80% of baseline authorizations to strip out fixed overhead. Management expects this operating cost reduction plan to ramp up significantly across 2026, which is critical for the promised H2 margin step-up.
Macro Headwind: ACA Exchange Membership Collapse
The macro environment is biting back. Evolent cited 'significant health plan customer membership decreases in their Exchange products' as a primary drag on 2026 EBITDA. The ACA Exchange population has previously seen elevated utilization, but as membership aggressively contracts—likely due to subsidy uncertainty and health plan pricing shifts—Evolent is losing a significant fee stream.
Enhanced Contract Model De-Risking
Evolent continues to transition its clients to the 'Enhanced Performance Suite' contract model, which utilizes bidirectional risk corridors. By capping both downside risk and upside potential, the company is sacrificing peak margin targets (aiming for ~10% instead of higher historical goals) to prevent the type of severe cost blowouts witnessed in early 2024.
Other KPIs
Decelerating violently. This is a massive drop from the $(30.6)M loss in 24Q4, driven entirely by the $398M goodwill impairment and higher administrative costs. The net loss margin for the quarter collapsed to (91.6)%.
Accelerating steadily. Up from 75.16 million a year ago and 78.05 million in 25Q3. This segment represents low-risk, fee-based revenue ($0.40 PMPM) that provides a stable foundation against the volatile Performance Suite.
Reversing positively from the end of 2024 ($104.2M), indicating that working capital management and collections improved in the back half of the year following the sluggish H1 cash flows.
Guidance
Accelerating. The midpoint of $2.5B represents massive 33% YoY growth compared to the $1.87B generated in FY25. This is fueled by $900M in new Performance Suite revenue.
Reversing. Despite 33% revenue growth, EBITDA is expected to drop 17% at the midpoint ($125M) vs FY25's $151.2M. Management blames front-loaded contract reserving effects and declining Exchange membership.
Stable. Consistent with the $35 million guidance given for FY25, indicating a steady, ongoing investment in the AuthIntel AI platform and core tech infrastructure.
Key Questions
Details on the $398M Goodwill Impairment
You recorded a massive $398 million goodwill impairment this quarter. Which specific reporting units or past acquisitions triggered this write-down, and does it change your view on the ROI of your historical M&A strategy?
Margin Ramp for the $900M Cohort
With $900 million in new Performance Suite revenue dragging down H1 2026 EBITDA due to reserving effects, exactly how many months will it take for this specific cohort to reach your target 10% mature margin?
Quantifying the ACA Exchange Hit
You cited significant membership decreases in Exchange products as a headwind. What baseline ACA Exchange membership is assumed in the 2026 guidance, and what is the specific EBITDA dollar impact of this contraction YoY?